Search research articles
Contact Us
Filters
Showing results (31-40 of 63) with videos related to
Page
of 7
Sort By:
Clinical Lung Cancer
|
October 11, 2024
A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol
J Spicer, N Blais, S Owen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
D S Hong, T M Bauer, J J Lee, et al.
Cell
|
March 18, 2014
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing
David G McFadden, Thales Papagiannakopoulos, Amaro Taylor-Weiner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Jessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Anna F Farago, Long P Le, Zongli Zheng, et al.
JCO Precision Oncology
|
January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non-Small-Cell Lung Cancer
Justin F Gainor, Diane Tseng, Satoshi Yoda, et al.
NPJ Precision Oncology
|
August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors
Aaron S Mansfield, David S Hong, Christine L Hann, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.
The Oncologist
|
June 3, 2026
Assessing Contribution of Effect in Oncology Combination Therapies: Lessons Learned to Inform and Optimize Future Registrational Trial Designs
Hillary Andrews, Raja Agnihotram, Gideon Blumenthal, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 63) with videos related to
Sort By:
Page
of 7
Clinical Lung Cancer
|
October 11, 2024
A Phase II Study of Neoadjuvant Opnurasib KRAS G12C Inhibitor in Patients With Surgically Resectable Non-Small Cell Lung Cancer (CCTG IND.242A): A Substudy of the IND.242 Platform Master Protocol
J Spicer, N Blais, S Owen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
D S Hong, T M Bauer, J J Lee, et al.
Cell
|
March 18, 2014
Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing
David G McFadden, Thales Papagiannakopoulos, Amaro Taylor-Weiner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
Jessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 14, 2015
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
Anna F Farago, Long P Le, Zongli Zheng, et al.
JCO Precision Oncology
|
January 16, 2018
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in <i>ROS1</i>-Positive Non-Small-Cell Lung Cancer
Justin F Gainor, Diane Tseng, Satoshi Yoda, et al.
NPJ Precision Oncology
|
August 6, 2021
A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors
Aaron S Mansfield, David S Hong, Christine L Hann, et al.
JTO Clinical and Research Reports
|
September 30, 2021
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
Biagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2021
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, et al.
The Oncologist
|
June 3, 2026
Assessing Contribution of Effect in Oncology Combination Therapies: Lessons Learned to Inform and Optimize Future Registrational Trial Designs
Hillary Andrews, Raja Agnihotram, Gideon Blumenthal, et al.
Page
of 7